Endometrial Carcinoma: A Comprehensive Analysis of Clinical Parameters, Treatment Modalities, and Prognostic Outcomes at a Tertiary Oncology Center in the UAE

被引:3
作者
Balaraj, Khalid S. [1 ]
Shanbhag, Nandan M. [1 ,2 ,3 ]
Bin Sumaida, Abdulrahman [1 ]
Hasnain, Syed Mansoor [4 ]
El-Koha, Omran A. [5 ]
Puratchipithan, Rajmane [5 ]
Kaabi, Khalifa M. Al [5 ]
Dawoud, Emad A. [6 ]
Nasim, Muhammad Y. [6 ]
Hassan, Thikra A.
Roy, Shilpi [5 ,7 ]
机构
[1] Tawam Hosp, Oncol Radiat Oncol, Al Ain, U Arab Emirates
[2] Tawam Hosp, Oncol Palliat Care, Al Ain, U Arab Emirates
[3] United Arab Emirtaes Univ, Oncol Internal Med, Al Ain, U Arab Emirates
[4] Tawam Hosp John Hopskins Med, Radiat Oncol, Al Ain, U Arab Emirates
[5] Tawam Hosp, Radiat Oncol, Al Ain, U Arab Emirates
[6] Tawam Hosp, Oncol, Al Ain, U Arab Emirates
[7] Tawam Hosp, Gynecol Oncol, Al Ain, U Arab Emirates
关键词
chemotherapy; adjuvant therapies; surgical intervention; treatment modalities; prognosis; microsatellite instability; pole ultramutated; molecular subtypes; uterine cancer; endometrial carcinoma; SURVIVAL; CANCER; MANAGEMENT; AGE; RADIOTHERAPY; DIAGNOSIS; OBESITY; IMPACT;
D O I
10.7759/cureus.48689
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Endometrial carcinoma (EC) remains a pressing global health issue, with a discernible upsurge in incidence, especially in developed countries. Notably, the United Arab Emirates (UAE) has witnessed a surge in EC cases, demanding an in-depth, region-specific exploration into the disease's clinical, treatment, and prognostic facets against the backdrop of its unique socio-genetic and environmental contours.Aim This study aimed to profess a comprehensive understanding of EC by examining clinical parameters, treatment modalities, and prognostic outcomes in the UAE context, thereby seeking to delineate potential correlations between varied therapeutic combinations, patient demographics, and tumor characteristics in affecting prognostic outcomes.Materials and methods A retrospective cohort study involving 93 patients diagnosed with EC from January 2011 to March 2023 at a leading oncology center in the UAE was conducted. Data, including demographic information, clinical presentation, treatment modalities, and prognostic outcomes, were meticulously extracted and analyzed. The R software (version 4.2.2) facilitated exhaustive statistical analyses, involving descriptive statistics, correlation analyses with the polycor package, and survival analyses utilizing the Kaplan-Meier method and Cox regression analysis via the survival and survminer packages, respectively.Results Although the correlation matrix revealed a noticeable relationship between "Family history" and "Age," most parameters displayed independence, offering a robust platform for ensuing multivariate analyses. Kaplan-Meier survival curves, stratified by therapeutic modalities, exhibited no statistically significant survival differences across therapeutic cohorts (p-values: 0.44, 0.86, and 0.83). Conversely, the composite Cox regression model underscored "non-national" demographic, Diabetes Mellitus II, and stromal invasion as pivotal prognostic factors, indicating the multifactorial nature of survival in EC patients and emphasizing demographic and tumor characteristics over therapeutic modalities as influential prognostic determinants.Conclusion In conclusion, while therapy types were not directly correlated with survival, demographic and tumor traits prominently impacted prognostic outcomes, advocating for an intricate, multidimensional approach to managing EC in the UAE. This study hopes to sow seeds for subsequent research, shaping clinically and culturally apt practices and policies in the region's healthcare landscape.
引用
收藏
页数:12
相关论文
共 33 条
  • [1] Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy-A population-based cohort study
    Akesson, Asa
    Adok, Claudia
    Dahm-Kahler, Pernilla
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 169 : 54 - 63
  • [2] Akhavan Setareh, 2016, World J Oncol, V7, P70, DOI 10.14740/wjon981w
  • [3] Time to surgery and its impact on survival in patients with endometrial cancer: A National cancer database study
    AlHilli, Mariam M.
    Elson, Paul
    Rybicki, Lisa
    Khorana, Alok A.
    Rose, Peter G.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 153 (03) : 511 - 516
  • [4] Adjuvant treatment of endometrial cancer today
    Aoki, Yoichi
    Kanao, Hiroyuki
    Wang, Xipeng
    Yunokawa, Mayu
    Omatsu, Kohei
    Fusegi, Atsushi
    Takeshima, Nobuhiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (07) : 753 - 765
  • [5] Braun MM, 2016, AM FAM PHYSICIAN, V93, P468
  • [6] Centers for Disease Control and Prevention, 2019, USCS data brief, no 11, DOI [10.15620/cdc:81916, DOI 10.15620/CDC:81916]
  • [7] ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
    Concin, Nicole
    Matias-Guiu, Xavier
    Vergote, Ignace
    Cibula, David
    Mirza, Mansoor Raza
    Marnitz, Simone
    Ledermann, Jonathan
    Bosse, Tjalling
    Chargari, Cyrus
    Fagotti, Anna
    Fotopoulou, Christina
    Gonzalez Martin, Antonio
    Lax, Sigurd
    Lorusso, Domenica
    Marth, Christian
    Morice, Philippe
    Nout, Remi A.
    O'Donnell, Dearbhaile
    Querleu, Denis
    Raspollini, Maria Rosaria
    Sehouli, Jalid
    Sturdza, Alina
    Taylor, Alexandra
    Westermann, Anneke
    Wimberger, Pauline
    Colombo, Nicoletta
    Planchamp, Francois
    Creutzberg, Carien L.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 12 - 39
  • [8] Endometrial cancer
    Crosbie, Emma J.
    Kitson, Sarah J.
    McAlpine, Jessica N.
    Mukhopadhyay, Asima
    Powell, Melanie E.
    Singh, Naveena
    [J]. LANCET, 2022, 399 (10333) : 1412 - 1428
  • [9] Proteogenomic insights suggest druggable pathways in endometrial carcinoma
    Dou, Yongchao
    Katsnelson, Lizabeth
    Gritsenko, Marina A.
    Hu, Yingwei
    Reva, Boris
    Hong, Runyu
    Wang, Yi-Ting
    Kolodziejczak, Iga
    Lu, Rita Jui-Hsien
    Tsai, Chia-Feng
    Bu, Wen
    Liu, Wenke
    Guo, Xiaofang
    An, Eunkyung
    Arend, Rebecca C.
    Bavarva, Jasmin
    Chen, Lijun
    Chu, Rosalie K.
    Czekanski, Andrzej
    Davoli, Teresa
    Demicco, Elizabeth G.
    Delair, Deborah
    Devereaux, Kelly
    Dhanasekaran, Saravana M.
    Dottino, Peter
    Dover, Bailee
    Fillmore, Thomas L.
    Foxall, McKenzie
    Hermann, Catherine E.
    Hiltke, Tara
    Hostetter, Galen
    Jedryka, Marcin
    Jewell, Scott D.
    Johnson, Isabelle
    Kahn, Andrea G.
    Ku, Amy T.
    Kumar-Sinha, Chandan
    Kurzawa, Pawel
    Lazar, Alexander J.
    Lazcano, Rossana
    Lei, Jonathan T.
    Li, Yi
    Liao, Yuxing
    Lih, Tung-Shing M.
    Lin, Tai-Tu
    Martignetti, John A.
    Masand, Ramya P.
    Matkowski, Rafal
    Mckerrow, Wilson
    Mesri, Mehdi
    [J]. CANCER CELL, 2023, 41 (09) : 1586 - +
  • [10] Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies
    Gong, Ting-Ting
    Wang, Yong-Lai
    Ma, Xiao-Xin
    [J]. SCIENTIFIC REPORTS, 2015, 5